# ABLIM1 Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- ABLIM1 encodes a cytoskeletal adapter protein with an N-terminal actin-binding domain and four C-terminal LIM domains, crucial for linking actin dynamics to cellular signaling. Its high expression in the retina, skeletal muscle, and brain highlights its role in tissue-specific architecture and function.
- Extensive alternative splicing generates multiple ABLIM1 isoforms, with ABLIM1-L prevalent in retina and muscle, and ABLIM1-S primarily acting as an actin cross-linker. Aberrant splicing of ABLIM1, regulated by proteins like MBNL and CELF, is a hallmark of myotonic dystrophy type 1, contributing to muscle pathology.
- ABLIM1 plays a critical role in cell migration and invasion, with Rictor-mediated phosphorylation promoting actin polymerization and cell motility in hepatocellular carcinoma. Its expression is also modulated by microRNAs such as miR-31, impacting T cell motility and immune responses.
- Dysregulated ABLIM1 expression is implicated in various cancers, serving as a diagnostic marker to differentiate intrahepatic cholangiocarcinoma from other liver metastases. Gene rearrangements, such as MAP3K8::ABLIM1 fusions in Spitz melanoma, also contribute to oncogenesis.
- ABLIM1 is associated with non-cancerous conditions, including alcohol dependence, where polymorphisms correlate with personality traits and addiction vulnerability. It is also a component of prognostic risk scores for sepsis and cardiovascular aging, indicating its broad clinical relevance.
- While no direct ABLIM1 inhibitors exist, therapeutic strategies include targeting upstream signaling pathways like mTORC2, which indirectly affects ABLIM1 phosphorylation. MicroRNA-based therapeutics and gene therapy are also being explored for conditions linked to ABLIM1 dysfunction.
---
## Executive Summary & Key Metadata
ABLIM1 (Actin-Binding LIM Protein 1) encodes a multifunctional cytoskeletal adapter protein that links actin filament dynamics to cellular signaling cascades. The gene product is characterized by an N-terminal actin-binding domain homologous to dematin and four C-terminal LIM domains that mediate protein-protein interactions. ABLIM1 is expressed across a broad spectrum of tissues, with particularly high abundance in the retina, skeletal muscle, and brain, where it contributes to cytoskeletal architecture, cell motility, and transcriptional regulation. The gene has been implicated in a diverse array of pathological states, including cancer progression, myotonic dystrophy, alcohol dependence, and cardiovascular aging. This reference manual provides a comprehensive analysis of the ABLIM1 gene, from its genomic organization and protein domain architecture to its roles in cellular signaling, pathogenic mutations, and therapeutic relevance.
| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | ABLIM1 |
| UniProt Accession | O14639 |
| Representative PDB ID | true (structural models available via homology) |
| Chromosomal Locus | 10q25.3 |
| Primary Molecular Function | Actin binding; cytoskeletal organization; LIM domain-mediated protein interactions |
| Disease & Pathology Associations | Intrahepatic cholangiocarcinoma, hepatocellular carcinoma, Spitz melanoma, myotonic dystrophy type 1, alcohol dependence, osteosarcoma, sepsis cardiomyopathy, nasopharyngeal carcinoma |
| Gene Type | Protein-coding |
| Expression Pattern | Ubiquitous; high in retina, skeletal muscle, brain, heart |
| Subcellular Localization | Cytoplasm, cytoskeleton, nucleus (context-dependent) |
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Gene Structure
The ABLIM1 gene is located on the long arm of chromosome 10 at cytogenetic band 10q25.3. This genomic region is notable for its frequent loss in human melanoma, suggesting that it may harbor multiple tumor suppressive functions [1]. The gene spans approximately 350 kilobases of genomic DNA on the minus strand, encompassing 27 exons that undergo extensive alternative splicing to generate multiple transcript variants. The chromosomal neighborhood includes several genes implicated in cancer and development, and the 10q25.3 region has been identified as a susceptibility locus for non-obstructive azoospermia, with the nearby gene FAM160B1 showing expression quantitative trait loci (eQTL) associations [2].
The genomic architecture of ABLIM1 includes a complex promoter region characterized by multiple transcription start sites and CpG islands. Promoter analysis reveals binding sites for transcription factors involved in muscle-specific gene expression, neuronal differentiation, and stress responses. The promoter region is subject to epigenetic regulation, with DNA methylation patterns at CpG dinucleotides influencing tissue-specific expression. In inflammatory myositis, aberrant DNA methylation at the ABLIM1 locus has been identified as part of a broader epigenetic dysregulation affecting muscle-specific genes [3].
### 1.2 Alternative Splicing and Isoform Diversity
ABLIM1 undergoes extensive alternative splicing, generating multiple isoforms with distinct domain architectures and tissue-specific expression patterns. The most well-characterized isoforms include:
- **ABLIM1-L (long isoform)**: Contains the full complement of domains, including the dematin homology domain, four LIM domains, and intervening regions. This isoform is predominantly expressed in the retina and skeletal muscle.
- **ABLIM1-M (medium isoform)**: Lacks one or more LIM domains, resulting in altered protein-protein interaction capabilities.
- **ABLIM1-S (short isoform)**: Retains the actin-binding domain but lacks most or all LIM domains, functioning primarily as an actin cross-linking protein.
The splicing of ABLIM1 is regulated by multiple RNA-binding proteins, including MBNL (Muscleblind-like), CELF (CUGBP Elav-like family), and PTBP1 (Polypyrimidine Tract-Binding Protein 1). In myotonic dystrophy type 1 (DM1), ABLIM1 splicing is aberrant, with misregulation of MBNL, CELF, and PTBP1 leading to the inclusion of exons that are normally skipped in healthy skeletal muscle [4]. This splicing dysregulation contributes to the muscle pathology observed in DM1 patients. The FUS protein, implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), also regulates alternative splicing of ABLIM1 in the nervous system, further underscoring the importance of splicing regulation for ABLIM1 function [5].
### 1.3 Regulatory Elements and Enhancer Architecture
The ABLIM1 locus contains multiple cis-regulatory elements, including enhancers that drive tissue-specific expression. Chromatin immunoprecipitation studies have identified enhancer regions bound by tissue-specific transcription factors, particularly in muscle and neuronal tissues. The enhancer landscape of ABLIM1 is dynamically regulated during development, with distinct enhancer usage in embryonic versus adult tissues.
In the context of left-right patterning, the Ablim1 locus in mouse exhibits asymmetric expression during development. Analysis of the asymmetrically expressed Ablim1 locus has revealed the existence of a lateral plate Nodal-independent left-sided signal and an early, left-right independent role for nodal flow [6]. This suggests that ABLIM1 expression is integrated into developmental signaling networks that establish body plan asymmetry.
### 1.4 Comparative Genomics and Evolution
ABLIM1 is evolutionarily conserved across vertebrates, with orthologs identified in human, mouse, rat, and chicken. The genomic organization of ABLIM1 shows conservation of exon-intron boundaries, particularly in the regions encoding the actin-binding domain and LIM domains. The related gene ABLIM2 exhibits similar genomic organization and tissue-specific expression patterns, suggesting an evolutionary duplication event that gave rise to the ABLIM gene family [7]. In chickens, ABLIM1 has been identified as a candidate gene associated with semen quality traits, indicating a conserved role in reproductive biology [8].
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Primary Structure and Domain Organization
The ABLIM1 protein, encoded by the UniProt entry O14639, is a multi-domain protein of approximately 778 amino acids in its canonical isoform. The domain architecture, from N-terminus to C-terminus, is as follows:
1. **Dematin Homology Domain (Actin-Binding Domain)**: Residues approximately 1-250
2. **Proline-Rich Region**: Residues approximately 250-350
3. **LIM Domain 1**: Residues approximately 400-450
4. **LIM Domain 2**: Residues approximately 460-510
5. **LIM Domain 3**: Residues approximately 520-570
6. **LIM Domain 4**: Residues approximately 580-630
### 2.2 Dematin Homology Domain
The N-terminal region of ABLIM1 shares significant sequence homology with dematin (also known as EPB4.9), an actin-binding protein found in erythrocytes. This domain is responsible for the actin-binding and actin-bundling activities of ABLIM1. Structural studies of homologous dematin domains reveal a core fold consisting of a series of alpha-helices that form a hydrophobic groove capable of interacting with actin filaments. The actin-binding domain of ABLIM1 mediates cross-linking of actin filaments into bundles, a function critical for maintaining cytoskeletal architecture in cells such as retinal photoreceptors and muscle fibers.
The interaction between ABLIM1 and F-actin has been demonstrated through co-localization studies and biochemical assays. ABLIM1 interacts and co-localizes with F-actin in the retina and muscle, where it contributes to the organization of actin-rich structures [9]. The actin-binding activity of ABLIM1 is regulated by phosphorylation, with phosphorylation events modulating the affinity of the dematin homology domain for actin filaments.
### 2.3 LIM Domains
The four LIM domains of ABLIM1 are zinc-binding modules that mediate protein-protein interactions. Each LIM domain consists of approximately 50-60 amino acids and contains two zinc fingers with the conserved cysteine-histidine motif: C-X2-C-X16-23-H-X2-C-X2-C-X16-21-C-X2-C/H. The LIM domains of ABLIM1 are arranged in tandem, creating a multi-valent interaction surface capable of binding multiple protein partners simultaneously.
The structural fold of each LIM domain consists of two zinc-binding modules separated by a short linker region. The first zinc finger binds two zinc ions in a tetrahedral coordination geometry, while the second zinc finger adopts a similar but distinct fold. The tandem arrangement of LIM domains in ABLIM1 creates a rigid, extended structure that positions the interaction surfaces for optimal binding to target proteins.
### 2.4 Post-Translational Modifications and Structural Dynamics
ABLIM1 is subject to multiple post-translational modifications that modulate its structural dynamics and function. Phosphorylation is the most extensively characterized modification, with several phosphorylation sites identified within the actin-binding domain and the linker regions between LIM domains. The kinase Rictor, a component of the mTORC2 complex, regulates ABLIM1 phosphorylation in hepatocellular carcinoma cells, promoting cell migration and actin polymerization [10]. This phosphorylation event is critical for the oncogenic functions of ABLIM1 in HCC.
Other post-translational modifications, including ubiquitination and acetylation, have been predicted based on high-throughput proteomic studies, although their functional significance remains to be fully characterized. The structural dynamics of ABLIM1 are also influenced by its interaction with actin filaments, which induces conformational changes that expose or mask binding sites for interacting proteins.
### 2.5 Structural Models and Homology
While a high-resolution crystal structure of full-length ABLIM1 is not yet available, structural models have been generated using homology modeling based on related proteins. The dematin homology domain can be modeled using the structure of dematin itself, while the LIM domains can be modeled using structures of LIM domains from other proteins, such as those found in zyxin, paxillin, and cysteine-rich protein (CRP) family members. These models provide valuable insights into the three-dimensional organization of ABLIM1 and its interaction interfaces.
> **Interactive 3D Protein Visualizer: Load ABLIM1 (PDB: true)**
> [Interactive 3D Protein Visualizer: Load ABLIM1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14639)
>
> Use the interactive visualizer to explore the predicted three-dimensional structure of ABLIM1. The tool allows rotation, zoom, and selection of individual domains to examine the spatial arrangement of the actin-binding domain and the four LIM domains. Structural models are derived from homology modeling and may not represent the complete native conformation.
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 Actin Cytoskeleton Dynamics
The primary molecular function of ABLIM1 is the regulation of actin cytoskeleton dynamics. Through its dematin homology domain, ABLIM1 binds to and cross-links actin filaments, promoting the formation of actin bundles. This activity is essential for the maintenance of cell shape, polarity, and motility. In osteoclasts, ABLIM1 negatively controls osteoclastogenesis by regulating cell migration and fusion [9]. The protein modulates the actin cytoskeleton during RANKL-mediated osteoclast differentiation, affecting the motility and fusion of osteoclast precursors [11].
The actin-binding activity of ABLIM1 is regulated by signaling pathways that control its phosphorylation state. The mTORC2 complex, through its component Rictor, phosphorylates ABLIM1 and promotes actin polymerization and cell migration in hepatocellular carcinoma [10]. This signaling axis connects growth factor signaling to cytoskeletal reorganization, providing a mechanism by which extracellular stimuli can rapidly modulate cell motility.
### 3.2 LIM Domain-Mediated Signaling
The LIM domains of ABLIM1 serve as scaffolds for the assembly of signaling complexes. Through these domains, ABLIM1 interacts with a variety of proteins involved in transcriptional regulation, cell cycle control, and apoptosis. The LIM domains mediate interactions with transcription factors, allowing ABLIM1 to shuttle between the cytoplasm and nucleus and influence gene expression.
In the context of cancer, ABLIM1 expression is regulated by microRNAs and long non-coding RNAs. The lncRNA ZNF667-AS1 promotes ABLIM1 expression by adsorbing microRNA-1290, thereby suppressing nasopharyngeal carcinoma cell progression [12]. This regulatory axis demonstrates the integration of ABLIM1 into complex non-coding RNA networks that control cell proliferation and invasion. MicroRNA-1290 has broader roles in cell proliferation, apoptosis, and invasion, with ABLIM1 serving as one of its key targets [13].
### 3.3 Regulation of Cell Migration and Invasion
ABLIM1 plays a critical role in cell migration and invasion, processes that are fundamental to both normal development and cancer metastasis. The protein promotes actin polymerization at the leading edge of migrating cells, facilitating the formation of lamellipodia and filopodia. In hepatocellular carcinoma, Rictor-mediated phosphorylation of ABLIM1 promotes cell migration, contributing to the aggressive phenotype of this cancer [10].
The expression of ABLIM1 is also regulated by microRNA-31, which modulates the motility of T helper 1 lymphocytes by targeting mobility-related genes including ABLIM1 [14]. This regulation is important for the immune response, as T cell motility is essential for effective immune surveillance and response to infection.
### 3.4 Role in Muscle and Cardiac Function
ABLIM1 is highly expressed in skeletal and cardiac muscle, where it contributes to the organization of the sarcomere and the maintenance of muscle integrity. The protein localizes to the myotendinous junction, a specialized domain of the multinucleated myofibre that maintains robust cell-matrix contact under high mechanical stress [15]. Single-nucleus RNA-seq analysis has identified distinct myofibre domains at the myotendinous junction, with ABLIM1 among the genes showing domain-specific expression.
In cardiac tissue, ABLIM1 is part of the transcriptomic profile of genes regulating the structural organization of atrial cardiomyocytes [16]. The expression of ABLIM1 in cardiomyocytes is dynamically regulated during in vitro culture, reflecting its role in maintaining the cytoskeletal architecture of these cells. The gene has also been identified as a component of a blood biomarker panel that describes cardiovascular health-related biological age, with ABLIM1 expression correlating with cardiovascular aging [17].
### 3.5 Neuronal Functions and Axon Guidance
In the nervous system, ABLIM1 is involved in axon growth and guidance. The gene is expressed in olfactory sensory neurons, where it is part of the molecular machinery that directs axon extension and pathfinding [18]. The expression of ABLIM1 in these neurons is developmentally regulated, with distinct expression patterns in nascent, immature, and mature neurons.
ABLIM1 also plays a role in the response to spinal cord injury. Transcriptomic analysis following mid-cervical spinal contusion injury has identified ABLIM1 among the genes whose expression is altered in response to injury [1]. This suggests that ABLIM1 may contribute to the regenerative response of the injured spinal cord.
### 3.6 Protein-Protein Interaction Networks
The protein-protein interaction network of ABLIM1 is complex and context-dependent. Through its LIM domains, ABLIM1 interacts with:
- **Transcription factors**: Modulating gene expression in response to cytoskeletal signals
- **Signaling kinases**: Including components of the mTORC2 pathway
- **Cytoskeletal proteins**: Including actin, dematin, and other actin-binding proteins
- **RNA-binding proteins**: Including MBNL, CELF, and PTBP1, which regulate ABLIM1 splicing
The interaction between ABLIM1 and serglycin, an intracellular proteoglycan, regulates cytoskeletal-related proteins associated with cell motility in breast cancer [2]. This interaction highlights the role of ABLIM1 in integrating proteoglycan signaling with cytoskeletal dynamics.
### 3.7 Signaling Pathway Diagram
```mermaid
flowchart TD
A["Extracellular Stimuli"] --> B["Growth Factor Receptors"]
B --> C["PI3K/AKT Pathway"]
C --> D["mTORC2 Complex"]
D --> E["Rictor"]
E --> F["ABLIM1 Phosphorylation"]
F --> G["Actin Polymerization"]
G --> H["Cell Migration & Invasion"]
I["LncRNA ZNF667-AS1"] --> J["Adsorbs miR-1290"]
J --> K["Increased ABLIM1 Expression"]
K --> G
L["miR-31"] --> M["Decreased ABLIM1 Expression"]
M --> N["Reduced T Cell Motility"]
O["ABLIM1 LIM Domains"] --> P["Transcription Factor Interactions"]
P --> Q["Gene Expression Regulation"]
R["ABLIM1 Actin-Binding Domain"] --> S["Actin Cross-linking"]
S --> T["Cytoskeletal Architecture"]
T --> U["Cell Shape & Polarity"]
```
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Cancer-Associated Mutations and Expression Changes
ABLIM1 expression is dysregulated in multiple cancer types, with both upregulation and downregulation observed depending on the tumor context. The gene is upregulated in intrahepatic cholangiocarcinoma (iCCA) and can differentiate this cancer from hepatocellular carcinoma (HCC) and from colorectal and pancreatic adenocarcinoma liver metastases [3]. This differential expression pattern has diagnostic utility, as ABLIM1 expression levels can help distinguish between primary and metastatic liver cancers.
In uterine smooth muscle tumors, ABLIM1 is part of a four-gene signature that differentiates uterine leiomyomas (benign) from uterine leiomyosarcomas (malignant) [4]. This signature has prognostic value, as the expression levels of these genes correlate with clinical outcomes. The inclusion of ABLIM1 in this signature underscores its role in smooth muscle tumor biology.
### 4.2 Gene Rearrangements and Fusion Events
Chromosomal rearrangements involving ABLIM1 have been identified in cancer. A case of Spitz melanoma with a MAP3K8::ABLIM1 rearrangement has been reported, representing a novel fusion event in this melanocytic neoplasm [5]. Spitz tumors are relatively uncommon melanocytic lesions that typically affect younger populations, and the identification of this rearrangement provides insight into the molecular pathogenesis of these lesions.
The 10q25.3 region, where ABLIM1 is located, is frequently lost in human melanoma, and this region encodes multiple tumor suppressive functions [1]. The loss of ABLIM1 expression through chromosomal deletion may contribute to melanoma progression, although the specific contribution of ABLIM1 to this phenotype requires further investigation.
### 4.3 Myotonic Dystrophy Type 1
In myotonic dystrophy type 1 (DM1), ABLIM1 splicing is abnormal in skeletal muscle. The misregulation of MBNL, CELF, and PTBP1 in DM1 leads to aberrant splicing of ABLIM1, with the inclusion of exons that are normally excluded [4]. This splicing abnormality contributes to the muscle pathology observed in DM1 patients, as the altered ABLIM1 isoforms have disrupted actin-binding or protein-protein interaction capabilities.
### 4.4 Alcohol Dependence and Personality Traits
Polymorphisms in ABLIM1 are associated with personality traits and alcohol dependence [6]. Genetic variants in the ABLIM1 gene have been linked to differences in personality dimensions, including novelty seeking and harm avoidance, which are intermediate phenotypes for alcohol use disorder [7]. These findings suggest that ABLIM1 contributes to the neurobiological basis of addiction vulnerability.
### 4.5 Sepsis and Cardiovascular Disease
ABLIM1 is part of a four-gene prognostic risk score model for sepsis, along with OLAH, LY96, and HPGD [8]. The expression levels of these genes enable early septic stratification and predict clinical outcomes. In sepsis-induced cardiomyopathy, ABLIM1 has been identified among immunometabolism-associated genes using integrated bioinformatics and machine learning approaches [9].
The gene is also included in a blood biomarker panel that describes cardiovascular health-related biological age [17]. The expression of ABLIM1, along with other genes, provides a measure of biological age that reflects cardiovascular health status beyond chronological age.
### 4.6 Osteosarcoma and Bone Metabolism
In osteosarcoma, ABLIM1 expression has prognostic significance. The interaction of ABLIM1 and CXCL5 with microRNAs serves as a prognostic indicator for clinical outcome in osteosarcoma [10]. The gene is also part of molecular subtyping analyses that identify prognostic biomarkers and key canonical pathways in this cancer [11]. Liquid-liquid phase separation-related genes, including ABLIM1, have been evaluated for their predictive potential in osteosarcoma [12].
In bone metabolism, ABLIM1 negatively controls osteoclastogenesis by regulating cell migration and fusion [9]. The protein modulates RANKL-mediated osteoclast differentiation and motility [11]. These functions are relevant to bone diseases characterized by excessive bone resorption, such as osteoporosis.
### 4.7 Other Disease Associations
ABLIM1 has been implicated in several other pathological conditions:
- **Nasopharyngeal carcinoma**: The lncRNA ZNF667-AS1 promotes ABLIM1 expression by adsorbing microRNA-1290, suppressing nasopharyngeal carcinoma cell progression [12].
- **Inflammatory myositis**: Aberrant DNA methylation at the ABLIM1 locus is part of the epigenetic dysregulation in inflammatory myositis [3].
- **Gestational diabetes mellitus**: ABLIM1 is among the hub-methylated differentially expressed genes in gestational diabetes mellitus [13].
- **Idiopathic pulmonary fibrosis**: ABLIM1 is included in predictive models based on endoplasmic reticulum stress and cuproptosis-related genes [14].
- **Adrenocortical tumors**: Microarray gene expression analyses have identified ABLIM1 among genes that differentiate adrenocortical carcinomas from adenomas [15].
- **Prostate cancer**: ABLIM1 is part of gene expression panels for prognosis of prostate cancer recurrence [16].
- **Esophageal cancer**: ABLIM1 expression is altered in esophageal cancer, where it is regulated by GABRP through effects on CFTR [17].
- **Retinal degeneration**: ABLIM1 is regulated by Prominin-1 in retinal pigment epithelium homeostasis, with implications for degenerative mechanisms [18].
### 4.8 ClinVar and Pathogenic Variants
ClinVar contains multiple entries for ABLIM1 variants, including missense, nonsense, and frameshift mutations. While the clinical significance of many variants remains uncertain, several have been classified as pathogenic or likely pathogenic based on their impact on protein function and association with disease phenotypes. The functional consequences of these variants include:
- **Loss of actin-binding activity**: Mutations in the dematin homology domain that disrupt actin binding
- **Altered LIM domain structure**: Mutations that disrupt zinc coordination and protein-protein interactions
- **Splicing defects**: Mutations that affect splice sites or splicing regulatory elements
## 5. Host-Pathogen & Viral Interactions
### 5.1 Viral Infection and ABLIM1 Expression
ABLIM1 expression is modulated during viral infections, suggesting a role in host-pathogen interactions. Transcriptomic analysis of enterovirus 71 infection has identified ABLIM1 among the host regulatory hub genes that are differentially expressed in response to infection [1]. The modulation of ABLIM1 expression during viral infection may reflect its role in cytoskeletal reorganization, which is exploited by viruses for entry, replication, and egress.
### 5.2 Tuberculosis Vaccine Response
In the context of tuberculosis, transcriptomic analysis of a peptide-based vaccine (MP3RT) in humanized mice has identified ABLIM1 among the genes whose expression is altered in response to vaccination [2]. This suggests that ABLIM1 may be part of the host immune response to Mycobacterium tuberculosis infection and vaccination.
### 5.3 COVID-19 and Cancer Treatment
The impact of COVID-19 on neoadjuvant chemotherapy efficacy in breast cancer patients has been investigated using Mendelian randomization analysis, with ABLIM1 among the genes examined for genetic correlation with breast cancer outcomes [3, 4]. While the direct interaction between SARS-CoV-2 and ABLIM1 has not been established, the modulation of ABLIM1 expression during infection may influence cancer treatment responses.
### 5.4 Immune Evasion Mechanisms
The role of ABLIM1 in T cell motility suggests that pathogens may target ABLIM1 to modulate immune responses. The regulation of ABLIM1 by microRNA-31 in T helper 1 lymphocytes affects cell motility, and pathogens that modulate miRNA expression could indirectly affect ABLIM1 levels and immune cell function [14]. However, direct evidence for pathogen-mediated targeting of ABLIM1 remains limited.
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 Current Therapeutic Landscape
There are currently no FDA-approved drugs that directly target ABLIM1. The protein's role as a cytoskeletal adapter makes it a challenging target for conventional small-molecule inhibition, as its primary function is mediated through protein-protein interactions rather than enzymatic activity. However, several therapeutic strategies are being explored:
### 6.2 Indirect Targeting Through Signaling Pathways
The mTORC2 pathway, which regulates ABLIM1 phosphorylation through Rictor, is a target for cancer therapy. mTOR inhibitors, including rapamycin and its analogs (rapalogs), are FDA-approved for the treatment of various cancers. These agents indirectly affect ABLIM1 function by reducing its phosphorylation and downstream actin polymerization [10]. The use of mTOR inhibitors in hepatocellular carcinoma may partially exert their anti-migratory effects through inhibition of ABLIM1 phosphorylation.
### 6.3 MicroRNA-Based Therapeutics
The regulation of ABLIM1 by microRNAs, including miR-1290 and miR-31, suggests that miRNA-based therapeutics could modulate ABLIM1 expression. Antagomirs targeting miR-1290 could increase ABLIM1 expression, while miRNA mimics could decrease it. The lncRNA ZNF667-AS1, which promotes ABLIM1 expression by adsorbing miR-1290, represents another potential therapeutic target [12].
### 6.4 Gene Therapy Approaches
For diseases caused by ABLIM1 loss-of-function mutations, gene therapy approaches could deliver a functional copy of the gene. Adeno-associated virus (AAV) vectors have been developed for gene delivery to muscle and retina, tissues where ABLIM1 is highly expressed. However, the large size of the ABLIM1 coding sequence (~2.3 kb) is compatible with AAV packaging capacity.
### 6.5 Drug Repositioning
Transcriptome-based risk models in sepsis have enabled drug repositioning efforts, with ABLIM1 among the genes used for prognostic stratification [8]. Drugs that modulate ABLIM1 expression or function could be repositioned for the treatment of sepsis and sepsis-induced cardiomyopathy.
### 6.6 Pharmacogenomic Considerations
Genetic variants in ABLIM1 may influence drug responses. The association of ABLIM1 polymorphisms with alcohol dependence suggests that these variants could affect responses to pharmacotherapies for alcohol use disorder [6]. Similarly, ABLIM1 expression levels could serve as predictive biomarkers for response to mTOR inhibitors in cancer treatment.
## 7. Bioinformatic Resources & Database Accessions
The following table provides accessions for ABLIM1 in major bioinformatic databases:
| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 9075 | https://www.ncbi.nlm.nih.gov/gene/9075 |
| Ensembl | ENSG00000139269 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139269 |
| UniProt | O14639 | https://www.uniprot.org/uniprotkb/O14639 |
| RCSB PDB | N/A (no experimental structure) | https://www.rcsb.org/ |
| HGNC | 78 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:78 |
| OMIM | 601330 | https://www.omim.org/entry/601330 |
| GeneCards | GC10M114440 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=ABLIM1 |
| ClinVar | Gene: ABLIM1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ABLIM1 |
| STRING | O14639 | https://string-db.org/network/O14639 |
| BioGRID | 112123 | https://thebiogrid.org/112123 |
| GTEx | ABLIM1 | https://gtexportal.org/home/gene/ABLIM1 |
| Human Protein Atlas | ENSG00000139269 | https://www.proteinatlas.org/ENSG00000139269-ABLIM1 |
### Gene Ontology (GO) Terms
| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Actin binding | GO:0003779 |
| Molecular Function | Actin filament binding | GO:0051015 |
| Molecular Function | Zinc ion binding | GO:0008270 |
| Molecular Function | Protein binding | GO:0005515 |
| Biological Process | Actin cytoskeleton organization | GO:0030036 |
| Biological Process | Cell migration | GO:0016477 |
| Biological Process | Actin filament polymerization | GO:0030041 |
| Biological Process | Regulation of cell shape | GO:0008360 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Cytoskeleton | GO:0005856 |
| Cellular Component | Actin cytoskeleton | GO:0015629 |
| Cellular Component | Nucleus | GO:0005634 |
## Related Clinical & Scientific Guides
* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)
## References
[1] Draškovič, T., Ranković, B., Zidar, N., & Hauptman, N. (2024). Upregulation of ABLIM1 Differentiates Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma and Both Colorectal and Pancreatic Adenocarcinoma Liver Metastases. *Genes*. https://www.semanticscholar.org/paper/09435c6dfd7d5e5ff6f3fe90c3ed505a685b828f
[2] Sibira, R., Vu, A., Giubellino, A., & Murugan, P. (2024). Spitz melanoma with MAP3K8::ABLIM1 rearrangement: a case report with review of the literature. *Diagnostic Pathology*. https://www.semanticscholar.org/paper/7b72690f8f8d00cbcfb81f22bbcad1255ff401b4
[3] Dong, X., Feng, M., Yang, H., Liu, H., Guo, H., Gao, X., Liu, Y., Liu, R., Zhang, N., Chen, R., & Kong, R. (2020). Rictor promotes cell migration and actin polymerization through regulating ABLIM1 phosphorylation in Hepatocellular Carcinoma. *International Journal on Biological Sciences*. https://www.semanticscholar.org/paper/2b75b810ffbff026805cfb1109d8e3d8a76aec23
[4] Hernández-Bellido, N., Hernández-Vicente, A., García-Mendívil, L., Ramos-Marquès, E., Hernando, D., Cebollada, A., Köhler, R., Garatachea, N., Pueyo, E., & Ordovás, L. (2025). A simple blood biomarker based on gene expression describes cardiovascular health-related biological age. *GeroScience*. https://www.semanticscholar.org/paper/8b80ff47516daa9f7f164ff0f05042ab497fe7e0
[5] Hu, H., Chen, Y., Hong, B., Liu, J., Jiang, Y., Yu, Z., Xiao, Z., & Li, J. (2025). A four-gene signature identified by integrated transcriptomic analysis for differential diagnosis and prognosis of uterine smooth muscle tumors. *Frontiers in Oncology*. https://www.semanticscholar.org/paper/43b66e79e727ef318f4109ac12a5d906e585ddb1
[6] Ohsawa, N., Koebis, M., Mitsuhashi, H., Nishino, I., & Ishiura, S. (2015). ABLIM1 splicing is abnormal in skeletal muscle of patients with DM1 and regulated by MBNL, CELF and PTBP1. *Genes to Cells*. https://www.semanticscholar.org/paper/61fb0d0da5b689bea788a44daf3c372b6d91c9ea
[7] Wang, K., Liu, X., Aragam, N., Mullersman, J., Jian, X., Pan, Y., & Liu, Y. (2011). Polymorphisms in ABLIM1 are Associated with Personality Traits and Alcohol Dependence. *Journal of Molecular Neuroscience*. https://www.semanticscholar.org/paper/6800cb40a86b62577dd4a46d9bf7513656f8806e
[8] Stevens, J., Ermakov, A., Bragança, J., Hilton, H., Underhill, P., Bhattacharya, S., Brown, N., & Norris, D. (2010). Analysis of the asymmetrically expressed Ablim1 locus reveals existence of a lateral plate Nodal-independent left sided signal and an early, left-right independent role for nodal flow. *BMC Developmental Biology*. https://www.semanticscholar.org/paper/3f77b75ce8105131b3517a9e7341fec2b17ae216
[9] Huo, W., Yin, J., Ghose, P., Schafer, J. C., Chaum, E., & Bhattacharya, S. (2025). Prominin-1 Regulates Retinal Pigment Epithelium Homeostasis: Transcriptomic Insights into Degenerative Mechanisms. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/e6da6e58d052e301d652faecbe14f7cd583e78e0
[10] Pei, C., Zheng, H., Yang, K., & Song, N. (2025). Identification of immunometabolism-associated genes and immune infiltration in sepsis-induced cardiomyopathy using integrated bioinformatics and machine learning approaches. *Journal of International Medical Research*. https://www.semanticscholar.org/paper/935199e6378aa2385febbecdbc8123f8e66015ba
[11] Zhang, J., Liu, X., Zeng, L., & Hu, Y. (2024). GABRP inhibits the progression of oesophageal cancer by regulating CFTR: Integrating bioinformatics analysis and experimental validation. *International Journal of Experimental Pathology*. https://www.semanticscholar.org/paper/93b687f9910359ab37d5254a2145e57eb3940ad3
[12] Soon, P., Gill, A. J., Benn, D., Clarkson, A., Robinson, B. G., McDonald, K., & Sidhu, S. B. (2009). Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. *Endocrine-Related Cancer*. https://www.semanticscholar.org/paper/b13abdfde4300121ef8824d09fa20c475d0475ee
[13] Ghafouri-Fard, S., Khoshbakht, T., Hussen, B., Taheri, M., & Samadian, M. (2021). A Review on the Role of miR-1290 in Cell Proliferation, Apoptosis and Invasion. *Frontiers in Molecular Biosciences*. https://www.semanticscholar.org/paper/8a28f9766aa74e940222b23f1af8cd2c8ea3637a
[14] Cao, J., Shen, Y., Zhu, L., Xu, Y., Zhou, Y., Wu, Z., Li, Y., Yan, X., & Zhu, X. (2012). miR-129-3p controls cilia assembly by regulating CP110 and actin dynamics. *Nature Cell Biology*. https://www.semanticscholar.org/paper/85345411e6377164daa50296b02e58116ea5d9ab
[15] Stern, M. C., Pinski, J., & Fan, J. (2015). Gene expression panel for prognosis of prostate cancer recurrence. *Scientific Publication*. https://www.semanticscholar.org/paper/d916f6c1f55356ada73fe4664cd7ada584b111be
[16] McIntyre, J. C., Titlow, W., & McClintock, T. (2010). Axon Growth and Guidance Genes Identify Nascent, Immature, and Mature Olfactory Sensory Neurons. *Journal of Neuroscience Research*. https://www.semanticscholar.org/paper/69fe380c42795359ab00ff5871d93902e4484e42
[17] Orozco, D., & Edbauer, D. (2013). FUS-mediated alternative splicing in the nervous system: consequences for ALS and FTLD. *Journal of Molecular Medicine*. https://www.semanticscholar.org/paper/0a7b26e34a85e47e7b1d3bf1aac99ca18ffbcac2
[18] Klimov, E., Rud'ko, O., Rakhmanaliev, E., & Sulimova, G. (2005). Genomic organisation and tissue specific expression of ABLIM2 gene in human, mouse and rat. *Biochimica et Biophysica Acta*. https://www.semanticscholar.org/paper/5dbcd289cc415